HK1049619A1 - Oral solution containing galanthamine and a sweetening agent. - Google Patents

Oral solution containing galanthamine and a sweetening agent.

Info

Publication number
HK1049619A1
HK1049619A1 HK03101718A HK03101718A HK1049619A1 HK 1049619 A1 HK1049619 A1 HK 1049619A1 HK 03101718 A HK03101718 A HK 03101718A HK 03101718 A HK03101718 A HK 03101718A HK 1049619 A1 HK1049619 A1 HK 1049619A1
Authority
HK
Hong Kong
Prior art keywords
solution containing
sweetening agent
oral solution
containing galanthamine
galanthamine
Prior art date
Application number
HK03101718A
Other languages
English (en)
Inventor
Marc Karel Jozel Francois
Tony Mathilde Jozef Kempen
Eddy Andre Joee De Proost
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1049619A1 publication Critical patent/HK1049619A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HK03101718A 1999-10-26 2003-03-10 Oral solution containing galanthamine and a sweetening agent. HK1049619A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203512 1999-10-26
PCT/EP2000/010203 WO2001030318A1 (en) 1999-10-26 2000-10-16 Oral solution containing galanthamine and a sweetening agent

Publications (1)

Publication Number Publication Date
HK1049619A1 true HK1049619A1 (en) 2003-05-23

Family

ID=8240778

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101718A HK1049619A1 (en) 1999-10-26 2003-03-10 Oral solution containing galanthamine and a sweetening agent.

Country Status (30)

Country Link
EP (1) EP1237539B1 (is)
JP (1) JP2003512415A (is)
KR (1) KR100502391B1 (is)
CN (1) CN1200691C (is)
AR (1) AR026243A1 (is)
AT (1) ATE306904T1 (is)
AU (1) AU780826C (is)
BG (1) BG65792B1 (is)
BR (1) BR0015025A (is)
CA (1) CA2388830C (is)
CZ (1) CZ301996B6 (is)
DE (1) DE60023341T2 (is)
DK (1) DK1237539T3 (is)
EA (1) EA005683B1 (is)
EE (1) EE05230B1 (is)
ES (1) ES2250211T3 (is)
HK (1) HK1049619A1 (is)
HR (1) HRP20020332B1 (is)
HU (1) HUP0203484A3 (is)
IL (2) IL149310A0 (is)
IS (1) IS2628B (is)
MX (1) MXPA02004149A (is)
NO (1) NO332096B1 (is)
PL (1) PL201694B1 (is)
SI (1) SI1237539T1 (is)
SK (1) SK285643B6 (is)
TW (1) TW592725B (is)
UA (1) UA76095C2 (is)
WO (1) WO2001030318A1 (is)
ZA (1) ZA200203313B (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
CA2535613A1 (en) * 2003-08-13 2005-02-24 Janssen Pharmaceutica, N.V. Treatment of sleep disorders with cholinesterase inhibitors
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
US8709521B2 (en) * 2007-05-22 2014-04-29 The Coca-Cola Company Sweetener compositions having enhanced sweetness and improved temporal and/or flavor profiles
SI2667715T1 (sl) * 2011-01-27 2017-11-30 Neuren Pharmaceuticals Limited Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline
US20140107130A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals, LLC Oral Solution Formulations of Aripiprazole
JP6457582B2 (ja) * 2017-04-14 2019-01-23 エルメッド エーザイ株式会社 ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
JPH10273435A (ja) * 1997-01-29 1998-10-13 Fujisawa Pharmaceut Co Ltd 内服用液剤

Also Published As

Publication number Publication date
NO332096B1 (no) 2012-06-18
AU1384901A (en) 2001-05-08
CA2388830A1 (en) 2001-05-03
SI1237539T1 (sl) 2006-04-30
ZA200203313B (en) 2003-11-26
AU780826C (en) 2006-02-16
CN1200691C (zh) 2005-05-11
CZ301996B6 (cs) 2010-09-01
DK1237539T3 (da) 2006-02-27
BG106534A (en) 2002-12-29
HRP20020332A2 (en) 2004-02-29
CN1382037A (zh) 2002-11-27
KR100502391B1 (ko) 2005-07-19
NO20022003D0 (no) 2002-04-26
MXPA02004149A (es) 2002-10-17
IS6291A (is) 2002-02-28
SK285643B6 (sk) 2007-05-03
EE05230B1 (et) 2009-12-15
UA76095C2 (en) 2006-07-17
EA200200486A1 (ru) 2002-10-31
WO2001030318A1 (en) 2001-05-03
HUP0203484A2 (hu) 2003-02-28
TW592725B (en) 2004-06-21
BR0015025A (pt) 2002-06-18
HUP0203484A3 (en) 2004-12-28
IL149310A0 (en) 2002-11-10
EP1237539B1 (en) 2005-10-19
DE60023341T2 (de) 2006-07-27
AU780826B2 (en) 2005-04-21
PL362849A1 (en) 2004-11-02
HRP20020332B1 (en) 2011-02-28
BG65792B1 (bg) 2009-12-31
SK5302002A3 (en) 2002-10-08
ES2250211T3 (es) 2006-04-16
ATE306904T1 (de) 2005-11-15
IS2628B (is) 2010-05-15
EE200200213A (et) 2003-06-16
KR20020026010A (ko) 2002-04-04
PL201694B1 (pl) 2009-04-30
IL149310A (en) 2006-12-10
EP1237539A1 (en) 2002-09-11
EA005683B1 (ru) 2005-04-28
DE60023341D1 (de) 2006-03-02
AR026243A1 (es) 2003-02-05
CA2388830C (en) 2006-09-19
NO20022003L (no) 2002-06-18
CZ20021329A3 (cs) 2002-08-14
JP2003512415A (ja) 2003-04-02

Similar Documents

Publication Publication Date Title
ZA200202480B (en) Oral dosage forms.
AU141207S (en) A capsule
HUP0203204A3 (en) Oral dosage forms
PL342515A1 (en) Drug administering device
EP1145714A4 (en) DRUGS
GB2340759B (en) Improvements in drug delivery devices
GB9930079D0 (en) Medicaments
ZA200203313B (en) Oral solution containing galanthamine and a sweetening agent.
GB2334805B (en) Oxygen dispenser
EP1201245A4 (en) FUNCTIONAL ORAL PREPARATIONS
EP1091783A4 (en) DISTRIBUTOR OF DRUGS
GB9828620D0 (en) Medicaments
GB9827865D0 (en) Medicament
IL126732A0 (en) Pro drug
GB9929040D0 (en) Medicaments
AU139311S (en) Floss container
HK1047232A1 (zh) 口服劑型
GB9904935D0 (en) Medicaments
GB9915111D0 (en) Millennium Time Capsule
GB9803615D0 (en) Gum spittoon
GB9810377D0 (en) Dose reminder device
GB9809797D0 (en) Time capsule
GB9827285D0 (en) Medicament
GB9817943D0 (en) Genostics and drugs
GB9822273D0 (en) Medicament dispenser

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20201015